Hodgkin Lymphoma as Second Malignancy during Continuing Chemotherapy for Childhood Acute Lymphoblastic Leukemia

Abstract

Acute lymphoblastic leukemia (ALL) is the most prevalent childhood malignancy in most parts of the world with a 5-year survival rate above 70%. Long-term survivors are at risk for treatment-related late effects and second malignant neoplasms (SMNs). SMNs occur with a mean latency of 6-6.7 years after ALL diagnosis but are rarely observed during maintenance chemotherapy (CT). Hodgkin lymphoma (HL) as a complication of ALL is very rare. We report two children with ALL who developed HL while receiving maintenance CT. Both received appropriate chemo- and radiotherapy (CT/RT) and have survived for more than10 years.

MDR-1 gene polymorphisms G2677T and C3435T in a case of Hodgkin’s variant of Richter’s syndrome

“…HL has been reported as a second malignancy during continued chemotherapy (20), and an altered expression of the MDR1 gene may represent an additional risk factor for developing a secondary cancer. In previous studies, a higher frequency of the T allele in position 3435 of MDR1, as well as the T allele at position 2677, were detected in patients with colorectal cancers as compared to healthy subjects.…”